Tc-99m-Labeled Benzothiazole And Stilbene Derivatives As Imaging Agents For A Beta Plaques In Cerebral Amyloid Angiopathy
Jia Jianhua,Cui Mengchao,Dai Jiapei,Wang Xuedan,Li Zijing,Yu Pingrong,Yang Yanping,Fu Hualong,Ding Yu-Shin,Jia Hongmei,Liu Boli
DOI: https://doi.org/10.1039/c3md00195d
2013-01-01
MedChemComm
Abstract:beta-Amyloid (A beta) plaques in the blood vessels of the brain are associated with cerebral amyloid angiopathy (CAA), which is a common cause of stroke and vascular diseases. Imaging agents that can differentiate between A beta plaques in the brain and those on the walls of cerebrovascular vessels will provide non-invasive biomarkers to interrogate the pathogenesis of CAA and give insights into the mechanisms, significance and impact of A beta-CAA for developing effective therapies for CAA and stroke. A new series of Tc-99m-labeled benzothiazole and stilbene derivatives with positive charge were developed and evaluated for selectively targeting A beta plaques in the blood vessels of the brain. The rhenium complexes 6, 7, 13 and 14 displayed medium binding affinity to A beta(1-42) aggregates with K-i values of 162, 37, 366 and 78 nM, respectively. In vitro fluorescence staining of 7 and 14 demonstrated an intense labeling of A beta plaques associated with blood vessel walls on brain sections of a patient with Alzheimer's diseases. A relatively low initial brain uptake for [Tc-99m]7 and [Tc-99m]14, 0.18 and 0.24 ID% per gram, respectively, suggests that they may be useful SPECT imaging agents for selectively detecting A beta plaques associated with cerebral vessels in the living human brain.